The effect of Ramadan fasting and continuing sodium-glucose co-transporter-2 (SGLT2) inhibitor use on ketonemia, blood pressure, and renal function in Muslim patients with type 2 diabetes | diabetes.medicinematters.com

Medicine Matters Diabetes

JAVASCRIPT NEEDED

Please enable JavaScript on your browser, so that you can use all features of this website.

window.dataLayer = window.dataLayer || []; window.dataLayer.push({ 'event': 'track', 'eventCategory': 'flash_warning', 'eventAction': 'Javascript needed', 'eventLabel': 'Please enable JavaScript on your browser, so that you can use all features of this website.' });

Top

05-24-2018 | Diet | Article

The effect of Ramadan fasting and continuing sodium-glucose co-transporter-2 (SGLT2) inhibitor use on ketonemia, blood pressure, and renal function in Muslim patients with type 2 diabetes

Shao Y et al. Diabetes Res Clin Prac 2018. doi: 10.1016/j.diabres.2018.05.022

Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.

https://doi.org/10.1016/j.diabres.2018.05.022

Version: 0.2002.0

Medicine Matters Diabetes

The effect of Ramadan fasting and continuing sodium-glucose co-transporter-2 (SGLT2) inhibitor use on ketonemia, blood pressure, and renal function in Muslim patients with type 2 diabetes

New additions to the Adis Journal Club

ADA 2022 coverage